home.social

#psychedelicresearch — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #psychedelicresearch, aggregated by home.social.

  1. Andrew Huberman has repeatedly emphasized that psychedelics interact with neuroplasticity and learning states.

    We are aligned with this direction.

    → Heightened plasticity increases the importance of post-experience infrastructure, monitoring, and continuity systems.

    #Psychedelics #Neuroscience #MentalHealth #PsychedelicResearch #Neuroplasticity #PublicHealth

  2. Andrew Huberman has repeatedly emphasized that psychedelics interact with neuroplasticity and learning states.

    We are aligned with this direction.

    → Heightened plasticity increases the importance of post-experience infrastructure, monitoring, and continuity systems.

    #Psychedelics #Neuroscience #MentalHealth #PsychedelicResearch #Neuroplasticity #PublicHealth

  3. Andrew Huberman has repeatedly emphasized that psychedelics interact with neuroplasticity and learning states.

    We are aligned with this direction.

    → Heightened plasticity increases the importance of post-experience infrastructure, monitoring, and continuity systems.

    #Psychedelics #Neuroscience #MentalHealth #PsychedelicResearch #Neuroplasticity #PublicHealth

  4. Andrew Huberman has repeatedly emphasized that psychedelics interact with neuroplasticity and learning states.

    We are aligned with this direction.

    → Heightened plasticity increases the importance of post-experience infrastructure, monitoring, and continuity systems.

    #Psychedelics #Neuroscience #MentalHealth #PsychedelicResearch #Neuroplasticity #PublicHealth

  5. Andrew Huberman has repeatedly emphasized that psychedelics interact with neuroplasticity and learning states.

    We are aligned with this direction.

    → Heightened plasticity increases the importance of post-experience infrastructure, monitoring, and continuity systems.

    #Psychedelics #Neuroscience #MentalHealth #PsychedelicResearch #Neuroplasticity #PublicHealth

  6. DATE: May 12, 2026 at 10:00AM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: Are the benefits of psychedelics exaggerated? A new study highlights the problem of selection bias

    URL: psypost.org/are-the-benefits-o

    A study comparing psychedelic enthusiasts and people from the general population (who also had psychedelic experiences) found that the enthusiasts tended to report much greater positive quality-of-life effects. The enthusiasts also showed higher openness, extraversion, and agreeableness. This indicates that recruitment strategies in psychedelic research that lean towards including enthusiasts may shape the outcomes obtained in those studies. The paper was published in the Journal of Psychoactive Drugs.

    Psychedelic drugs are substances that can strongly alter perception, mood, thinking, and the sense of self. They may change how people experience colors, sounds, time, memories, emotions, and the meaning of events. Classic psychedelics include LSD, psilocybin from “magic mushrooms,” DMT, and mescaline. These substances mainly act on serotonin receptors in the brain.

    In research settings, psychedelics are being studied for possible therapeutic use in conditions such as depression, PTSD, anxiety, and substance use disorders. Their effects depend heavily on dose, personality, expectations, mental state, physical setting, and social support. Psychedelics can also carry risks, including panic, confusion, dangerous behavior during intoxication, worsening of some psychiatric conditions, and legal consequences where they are prohibited.

    Study author Jonathan Bendz and his colleagues noted that many studies of psychedelic users report extraordinarily positive self-reported effects. However, they suggest that this might represent an exaggeration of the real effects caused by biased selection, or even self-selection, of study participants. The issue is that the effects of psychedelics can only be tested on individuals who agree to use them. These participants tend to be individuals who have already had especially positive experiences with psychedelic use.

    To examine this hypothesis, these researchers conducted a study comparing whether the self-reported quality-of-life impact of psychedelic experiences differed between a convenience sample of psychedelic enthusiasts and a group of people from the general population recruited via Prolific. They also wanted to see whether the difference between the two groups remained after controlling for mindset, setting, motivation to use psychedelic drugs, and personality traits.

    The enthusiast group consisted of 583 individuals recruited through an anonymous survey posted on the Facebook and Instagram pages of a Swedish nonprofit organization that disseminates information about psychedelic science (Nätverket för Psykedelisk Vetenskap). A snowball sampling approach was used to reach more participants. The general population group consisted of 599 individuals recruited via Prolific (an online survey platform). They were required to have prior psychedelic experience, but were not recruited from a specific psychedelic community.

    Study participants completed assessments of the quality-of-life impact of their psychedelic experiences (e.g., “How has your most meaningful psychedelic experience affected the quality of your relationship with… family, friends, yourself, society, and nature?”). They also answered questions regarding their mindset and physical setting during the experience (“To what extent did you experience your mindset/environment to be optimal?”), their motivation (“What was your motivation for using a psychedelic substance?”), and their personality (using the IPIP-NEO-30 assessment).

    Results showed that the psychedelic enthusiasts tended to report a much higher quality-of-life impact from their psychedelic experiences compared to the Prolific group. The enthusiast group also reported having a more optimal mindset and setting during their trips, and they were more likely to report taking the drugs for personal growth rather than for fun. Finally, the enthusiasts tended to be more open to new experiences, extraverted, and agreeable than the participants from the Prolific group.

    Even after using a statistical model to account for these differences in personality, mindset, setting, and motivation, simply belonging to the enthusiast group remained the strongest predictor of reporting a high quality-of-life impact.

    “As expected, participants recruited from an enthusiast-leaning channel reported considerably greater benefits [of psychedelic use] than those recruited from a general-population platform. Even after controlling for mindset, setting, motivation, and personality, sample membership remained the strongest predictor of quality-of-life impact,” the study authors concluded.

    “The persistent effect of sample membership suggests that the two groups differ in additional ways not captured by our measures, for example in cultural expectations, social context, or demographic composition, shaping reported outcomes. These results underscore the need for caution when interpreting findings from psychedelic studies that rely on highly engaged user populations.”

    The study sheds light on important methodological issues that studies of psychedelic effects face. However, the authors note some limitations. For example, the two groups had demographic differences; the general sample was overwhelmingly from the United States, while the enthusiast sample lacked country-of-residence data for most participants (though a portion resided in Sweden). This introduces the possibility of cross-cultural differences influencing the results.

    Additionally, it should be noted that the Prolific sample likely included many psychedelic enthusiasts as well. Because of this, the difference between the two groups in this study likely underestimates the true difference between the general population and psychedelic enthusiasts.

    The paper, “Selection Bias in Psychedelic Research: Comparing Self-Reported Quality-Of-Life Impact Between Enthusiasts and a General Population Sample,” was authored by Jonathan Bendz, Linus Schäfer, David Sjöström, Sverker Sikström, and Petri Kajonius.

    URL: psypost.org/are-the-benefits-o

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Psychedelics #SelectionBias #QualityOfLife #PsychedelicResearch #StudyBias #OpenMindedness #PersonalityTraits #MentalHealthResearch #TherapeuticPsychedelics #ScientificCaution

  7. DATE: May 12, 2026 at 10:00AM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: Are the benefits of psychedelics exaggerated? A new study highlights the problem of selection bias

    URL: psypost.org/are-the-benefits-o

    A study comparing psychedelic enthusiasts and people from the general population (who also had psychedelic experiences) found that the enthusiasts tended to report much greater positive quality-of-life effects. The enthusiasts also showed higher openness, extraversion, and agreeableness. This indicates that recruitment strategies in psychedelic research that lean towards including enthusiasts may shape the outcomes obtained in those studies. The paper was published in the Journal of Psychoactive Drugs.

    Psychedelic drugs are substances that can strongly alter perception, mood, thinking, and the sense of self. They may change how people experience colors, sounds, time, memories, emotions, and the meaning of events. Classic psychedelics include LSD, psilocybin from “magic mushrooms,” DMT, and mescaline. These substances mainly act on serotonin receptors in the brain.

    In research settings, psychedelics are being studied for possible therapeutic use in conditions such as depression, PTSD, anxiety, and substance use disorders. Their effects depend heavily on dose, personality, expectations, mental state, physical setting, and social support. Psychedelics can also carry risks, including panic, confusion, dangerous behavior during intoxication, worsening of some psychiatric conditions, and legal consequences where they are prohibited.

    Study author Jonathan Bendz and his colleagues noted that many studies of psychedelic users report extraordinarily positive self-reported effects. However, they suggest that this might represent an exaggeration of the real effects caused by biased selection, or even self-selection, of study participants. The issue is that the effects of psychedelics can only be tested on individuals who agree to use them. These participants tend to be individuals who have already had especially positive experiences with psychedelic use.

    To examine this hypothesis, these researchers conducted a study comparing whether the self-reported quality-of-life impact of psychedelic experiences differed between a convenience sample of psychedelic enthusiasts and a group of people from the general population recruited via Prolific. They also wanted to see whether the difference between the two groups remained after controlling for mindset, setting, motivation to use psychedelic drugs, and personality traits.

    The enthusiast group consisted of 583 individuals recruited through an anonymous survey posted on the Facebook and Instagram pages of a Swedish nonprofit organization that disseminates information about psychedelic science (Nätverket för Psykedelisk Vetenskap). A snowball sampling approach was used to reach more participants. The general population group consisted of 599 individuals recruited via Prolific (an online survey platform). They were required to have prior psychedelic experience, but were not recruited from a specific psychedelic community.

    Study participants completed assessments of the quality-of-life impact of their psychedelic experiences (e.g., “How has your most meaningful psychedelic experience affected the quality of your relationship with… family, friends, yourself, society, and nature?”). They also answered questions regarding their mindset and physical setting during the experience (“To what extent did you experience your mindset/environment to be optimal?”), their motivation (“What was your motivation for using a psychedelic substance?”), and their personality (using the IPIP-NEO-30 assessment).

    Results showed that the psychedelic enthusiasts tended to report a much higher quality-of-life impact from their psychedelic experiences compared to the Prolific group. The enthusiast group also reported having a more optimal mindset and setting during their trips, and they were more likely to report taking the drugs for personal growth rather than for fun. Finally, the enthusiasts tended to be more open to new experiences, extraverted, and agreeable than the participants from the Prolific group.

    Even after using a statistical model to account for these differences in personality, mindset, setting, and motivation, simply belonging to the enthusiast group remained the strongest predictor of reporting a high quality-of-life impact.

    “As expected, participants recruited from an enthusiast-leaning channel reported considerably greater benefits [of psychedelic use] than those recruited from a general-population platform. Even after controlling for mindset, setting, motivation, and personality, sample membership remained the strongest predictor of quality-of-life impact,” the study authors concluded.

    “The persistent effect of sample membership suggests that the two groups differ in additional ways not captured by our measures, for example in cultural expectations, social context, or demographic composition, shaping reported outcomes. These results underscore the need for caution when interpreting findings from psychedelic studies that rely on highly engaged user populations.”

    The study sheds light on important methodological issues that studies of psychedelic effects face. However, the authors note some limitations. For example, the two groups had demographic differences; the general sample was overwhelmingly from the United States, while the enthusiast sample lacked country-of-residence data for most participants (though a portion resided in Sweden). This introduces the possibility of cross-cultural differences influencing the results.

    Additionally, it should be noted that the Prolific sample likely included many psychedelic enthusiasts as well. Because of this, the difference between the two groups in this study likely underestimates the true difference between the general population and psychedelic enthusiasts.

    The paper, “Selection Bias in Psychedelic Research: Comparing Self-Reported Quality-Of-Life Impact Between Enthusiasts and a General Population Sample,” was authored by Jonathan Bendz, Linus Schäfer, David Sjöström, Sverker Sikström, and Petri Kajonius.

    URL: psypost.org/are-the-benefits-o

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Psychedelics #SelectionBias #QualityOfLife #PsychedelicResearch #StudyBias #OpenMindedness #PersonalityTraits #MentalHealthResearch #TherapeuticPsychedelics #ScientificCaution

  8. DATE: May 12, 2026 at 10:00AM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: Are the benefits of psychedelics exaggerated? A new study highlights the problem of selection bias

    URL: psypost.org/are-the-benefits-o

    A study comparing psychedelic enthusiasts and people from the general population (who also had psychedelic experiences) found that the enthusiasts tended to report much greater positive quality-of-life effects. The enthusiasts also showed higher openness, extraversion, and agreeableness. This indicates that recruitment strategies in psychedelic research that lean towards including enthusiasts may shape the outcomes obtained in those studies. The paper was published in the Journal of Psychoactive Drugs.

    Psychedelic drugs are substances that can strongly alter perception, mood, thinking, and the sense of self. They may change how people experience colors, sounds, time, memories, emotions, and the meaning of events. Classic psychedelics include LSD, psilocybin from “magic mushrooms,” DMT, and mescaline. These substances mainly act on serotonin receptors in the brain.

    In research settings, psychedelics are being studied for possible therapeutic use in conditions such as depression, PTSD, anxiety, and substance use disorders. Their effects depend heavily on dose, personality, expectations, mental state, physical setting, and social support. Psychedelics can also carry risks, including panic, confusion, dangerous behavior during intoxication, worsening of some psychiatric conditions, and legal consequences where they are prohibited.

    Study author Jonathan Bendz and his colleagues noted that many studies of psychedelic users report extraordinarily positive self-reported effects. However, they suggest that this might represent an exaggeration of the real effects caused by biased selection, or even self-selection, of study participants. The issue is that the effects of psychedelics can only be tested on individuals who agree to use them. These participants tend to be individuals who have already had especially positive experiences with psychedelic use.

    To examine this hypothesis, these researchers conducted a study comparing whether the self-reported quality-of-life impact of psychedelic experiences differed between a convenience sample of psychedelic enthusiasts and a group of people from the general population recruited via Prolific. They also wanted to see whether the difference between the two groups remained after controlling for mindset, setting, motivation to use psychedelic drugs, and personality traits.

    The enthusiast group consisted of 583 individuals recruited through an anonymous survey posted on the Facebook and Instagram pages of a Swedish nonprofit organization that disseminates information about psychedelic science (Nätverket för Psykedelisk Vetenskap). A snowball sampling approach was used to reach more participants. The general population group consisted of 599 individuals recruited via Prolific (an online survey platform). They were required to have prior psychedelic experience, but were not recruited from a specific psychedelic community.

    Study participants completed assessments of the quality-of-life impact of their psychedelic experiences (e.g., “How has your most meaningful psychedelic experience affected the quality of your relationship with… family, friends, yourself, society, and nature?”). They also answered questions regarding their mindset and physical setting during the experience (“To what extent did you experience your mindset/environment to be optimal?”), their motivation (“What was your motivation for using a psychedelic substance?”), and their personality (using the IPIP-NEO-30 assessment).

    Results showed that the psychedelic enthusiasts tended to report a much higher quality-of-life impact from their psychedelic experiences compared to the Prolific group. The enthusiast group also reported having a more optimal mindset and setting during their trips, and they were more likely to report taking the drugs for personal growth rather than for fun. Finally, the enthusiasts tended to be more open to new experiences, extraverted, and agreeable than the participants from the Prolific group.

    Even after using a statistical model to account for these differences in personality, mindset, setting, and motivation, simply belonging to the enthusiast group remained the strongest predictor of reporting a high quality-of-life impact.

    “As expected, participants recruited from an enthusiast-leaning channel reported considerably greater benefits [of psychedelic use] than those recruited from a general-population platform. Even after controlling for mindset, setting, motivation, and personality, sample membership remained the strongest predictor of quality-of-life impact,” the study authors concluded.

    “The persistent effect of sample membership suggests that the two groups differ in additional ways not captured by our measures, for example in cultural expectations, social context, or demographic composition, shaping reported outcomes. These results underscore the need for caution when interpreting findings from psychedelic studies that rely on highly engaged user populations.”

    The study sheds light on important methodological issues that studies of psychedelic effects face. However, the authors note some limitations. For example, the two groups had demographic differences; the general sample was overwhelmingly from the United States, while the enthusiast sample lacked country-of-residence data for most participants (though a portion resided in Sweden). This introduces the possibility of cross-cultural differences influencing the results.

    Additionally, it should be noted that the Prolific sample likely included many psychedelic enthusiasts as well. Because of this, the difference between the two groups in this study likely underestimates the true difference between the general population and psychedelic enthusiasts.

    The paper, “Selection Bias in Psychedelic Research: Comparing Self-Reported Quality-Of-Life Impact Between Enthusiasts and a General Population Sample,” was authored by Jonathan Bendz, Linus Schäfer, David Sjöström, Sverker Sikström, and Petri Kajonius.

    URL: psypost.org/are-the-benefits-o

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Psychedelics #SelectionBias #QualityOfLife #PsychedelicResearch #StudyBias #OpenMindedness #PersonalityTraits #MentalHealthResearch #TherapeuticPsychedelics #ScientificCaution

  9. Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes

    New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.

    #PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression

    newsletter.tf/psychedelics-low

  10. Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes

    New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.

    #PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression

    newsletter.tf/psychedelics-low

  11. Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes

    New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.

    #PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression

    newsletter.tf/psychedelics-low

  12. Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes

    New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.

    #PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression

    newsletter.tf/psychedelics-low

  13. Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes

    New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.

    #PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression

    newsletter.tf/psychedelics-low

  14. TEXT MESSAGE SHAKES UP DRUG POLICY LANDSCAPE

    President Trump signed an order to speed up research on psychedelic drugs after a text from Joe Rogan. Find out how this affects medical trials.

    #PsychedelicResearch, #JoeRogan, #DonaldTrump, #DrugPolicy, #Ibogaine

    newsletter.tf/rogan-text-trump

  15. President Trump signed an executive order to speed up research on psychedelic drugs. This is a major policy change following a text message from Joe Rogan.

    #PsychedelicResearch, #JoeRogan, #DonaldTrump, #DrugPolicy, #Ibogaine
    newsletter.tf/rogan-text-trump

  16. They served us. Now we serve them. Veterans and first responders deserve every tool available for mental health— including safe, research-backed psychedelic therapy. It’s time to move from stigma to solutions. 🇺🇸 #Veterans #FirstResponders #MentalHealth #PsychedelicResearch #PTSD #EndTheStigma

  17. They served us. Now we serve them. Veterans and first responders deserve every tool available for mental health— including safe, research-backed psychedelic therapy. It’s time to move from stigma to solutions. 🇺🇸 #Veterans #FirstResponders #MentalHealth #PsychedelicResearch #PTSD #EndTheStigma

  18. "A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months.

    The study involved 198 adults with generalized anxiety disorder, ...

    ... people who received higher doses (100 or 200 micrograms) responded quickly, a team reports in the Journal of the American Medical Association."

    npr.org/sections/shots-health-

    #mentalhealth #anxiety #PsychedelicSunday #medicalnews #LSDStudy #psychedelics #lsd #neuroscience #psychedelictherapy #anxietyrelief #psychedelicresearch

  19. "A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months.

    The study involved 198 adults with generalized anxiety disorder, ...

    ... people who received higher doses (100 or 200 micrograms) responded quickly, a team reports in the Journal of the American Medical Association."

    npr.org/sections/shots-health-

    #mentalhealth #anxiety #PsychedelicSunday #medicalnews #LSDStudy #psychedelics #lsd #neuroscience #psychedelictherapy #anxietyrelief #psychedelicresearch

  20. "A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months.

    The study involved 198 adults with generalized anxiety disorder, ...

    ... people who received higher doses (100 or 200 micrograms) responded quickly, a team reports in the Journal of the American Medical Association."

    npr.org/sections/shots-health-

    #mentalhealth #anxiety #PsychedelicSunday #medicalnews #LSDStudy #psychedelics #lsd #neuroscience #psychedelictherapy #anxietyrelief #psychedelicresearch

  21. "A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months.

    The study involved 198 adults with generalized anxiety disorder, ...

    ... people who received higher doses (100 or 200 micrograms) responded quickly, a team reports in the Journal of the American Medical Association."

    npr.org/sections/shots-health-

    #mentalhealth #anxiety #PsychedelicSunday #medicalnews #LSDStudy #psychedelics #lsd #neuroscience #psychedelictherapy #anxietyrelief #psychedelicresearch

  22. "A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months.

    The study involved 198 adults with generalized anxiety disorder, ...

    ... people who received higher doses (100 or 200 micrograms) responded quickly, a team reports in the Journal of the American Medical Association."

    npr.org/sections/shots-health-

    #mentalhealth #anxiety #PsychedelicSunday #medicalnews #LSDStudy #psychedelics #lsd #neuroscience #psychedelictherapy #anxietyrelief #psychedelicresearch

  23. Mirá #uruguay este capítulo en el que participé sobre cómo la ketamina puede utilizarse en cuidados paliativos como una medicina psicodélica profundamente transformadora. — Psicodélicos en Cuidados Paliativos Psychedelics in Palliative Care: Ketamine Marcia Glass, ED. 2025, Oxford University Press academic.oup.com/book/60443/ch #psicodelicos #terapiaconketamina #ketamina #cuidadospaliativos #medicinapsicodelica #uruguay #psychedelicresearch #psychedelics #ketamine #psychedelic #palliativecare

  24. Mirá #uruguay este capítulo en el que participé sobre cómo la ketamina puede utilizarse en cuidados paliativos como una medicina psicodélica profundamente transformadora. — Psicodélicos en Cuidados Paliativos Psychedelics in Palliative Care: Ketamine Marcia Glass, ED. 2025, Oxford University Press academic.oup.com/book/60443/ch #psicodelicos #terapiaconketamina #ketamina #cuidadospaliativos #medicinapsicodelica #uruguay #psychedelicresearch #psychedelics #ketamine #psychedelic #palliativecare

  25. Mirá #uruguay este capítulo en el que participé sobre cómo la ketamina puede utilizarse en cuidados paliativos como una medicina psicodélica profundamente transformadora. — Psicodélicos en Cuidados Paliativos Psychedelics in Palliative Care: Ketamine Marcia Glass, ED. 2025, Oxford University Press academic.oup.com/book/60443/ch #psicodelicos #terapiaconketamina #ketamina #cuidadospaliativos #medicinapsicodelica #uruguay #psychedelicresearch #psychedelics #ketamine #psychedelic #palliativecare

  26. Mirá #uruguay este capítulo en el que participé sobre cómo la ketamina puede utilizarse en cuidados paliativos como una medicina psicodélica profundamente transformadora. — Psicodélicos en Cuidados Paliativos Psychedelics in Palliative Care: Ketamine Marcia Glass, ED. 2025, Oxford University Press academic.oup.com/book/60443/ch #psicodelicos #terapiaconketamina #ketamina #cuidadospaliativos #medicinapsicodelica #uruguay #psychedelicresearch #psychedelics #ketamine #psychedelic #palliativecare

  27. Mirá #uruguay este capítulo en el que participé sobre cómo la ketamina puede utilizarse en cuidados paliativos como una medicina psicodélica profundamente transformadora. — Psicodélicos en Cuidados Paliativos Psychedelics in Palliative Care: Ketamine Marcia Glass, ED. 2025, Oxford University Press academic.oup.com/book/60443/ch #psicodelicos #terapiaconketamina #ketamina #cuidadospaliativos #medicinapsicodelica #uruguay #psychedelicresearch #psychedelics #ketamine #psychedelic #palliativecare